Bleeding Disorders Integrated Hematology/Oncology Module

Hemophilia A is characterized by deficiency of factor IX.

Clinical manifestation of anti-phospholipid syndrome may include both transient ischemic stroke and blood in the urine.

Plasmapheresis is a potential treatment option for controlling progressive thromboembolism in patients with Catastrophic Antiphospholipid Syndrome (CAPS).

Pharmacists do not play a significant role in managing blood disorders.

Hemophilia B is characterized by deficiency of factor IX.

What is the direct cost of care related to hemophilia A in 2008?

In which type of bleeding disorder is there a congenital deficiency in a plasma coagulation protein?

What is the approximate number of males in the US affected by hemophilia A?

Which organization has published 2021 guidelines on the management of von Willebrand disease?

What is a potential complication for patients with hemophilia A in terms of healthcare costs?

What is the recommended treatment for antiphospholipid syndrome in adults according to EULAR?

What is the inheritance pattern of Hemophilia B?

Which factor is deficient in Hemophilia A?

What percentage of all patients with hemophilia have Hemophilia A?

In terms of circulating factor levels, which category of hemophilia is defined as 'severe'?

Which of the following is a clinical manifestation of anti-phospholipid syndrome in a newly diagnosed patient?

What is the primary treatment for controlling progressive thromboembolism in patients with Catastrophic Antiphospholipid Syndrome (CAPS)?

What role do pharmacists play in managing blood disorders?

Which blood disorder may require acute management and prophylaxis due to potential complications?

How are DOACs (Direct Oral Anticoagulants) used in the context of typical VTE?

What are the potential treatments for Catastrophic Antiphospholipid Syndrome (CAPS)?